Haemonetics 

$76.91
18
-$1.29-1.65% Monday 20:00

Statistics

Day High
78.43
Day Low
75.93
52W High
87.32
52W Low
47.32
Volume
701,588
Avg. Volume
-
Mkt Cap
3.57B
P/E Ratio
37.52
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
1.01
1.11
1.21
1.31
Expected EPS
1.086299
Actual EPS
N/A

Financials

12.32%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
2.72BRevenue
335.36MNet Income

Analyst Ratings

79.00Average Price Target
The highest estimate is 89.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HAE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Baxter International
BAX
Mkt Cap10.77B
Baxter International Inc. offers a range of products in blood and plasma collection, a direct competition to Haemonetics' blood processing systems.
Becton Dickinson
BDX
Mkt Cap40.3B
Becton, Dickinson and Company provides a variety of medical devices and supplies, including blood collection and management solutions, competing in similar markets as Haemonetics.
Thermo Fisher Scientific
TMO
Mkt Cap174.42B
Thermo Fisher Scientific Inc. supplies a wide range of laboratory equipment and consumables, including those for blood and plasma collection and analysis, overlapping with Haemonetics' offerings.
Danaher
DHR
Mkt Cap127.47B
Danaher Corporation's life sciences and diagnostics segments offer products and solutions that compete with Haemonetics in the blood management and diagnostics market.
Mettler-Toledo International
MTD
Mkt Cap22.86B
Mettler-Toledo International Inc. competes in the precision instruments sector, including laboratory equipment and diagnostics that can be used in blood analysis, indirectly competing with Haemonetics.
Resmed
RMD
Mkt Cap28.25B
ResMed Inc. is more focused on sleep and respiratory care, but its expansion into healthcare solutions and monitoring technologies presents a competitive edge in the broader healthcare market against Haemonetics.
Boston Scientific
BSX
Mkt Cap69.72B
Boston Scientific Corporation, while primarily focused on medical devices for interventional medical specialties, competes in the healthcare market where Haemonetics also operates, especially in patient care and treatment technologies.
Stryker
SYK
Mkt Cap119.69B
Stryker Corporation, known for medical devices and equipment, competes in the healthcare market, offering products that can be used in surgeries and medical treatments where blood management is crucial.
Abbott Laboratories
ABT
Mkt Cap153.59B
Abbott Laboratories offers a broad range of healthcare products, including diagnostics and medical devices that compete with Haemonetics in the healthcare and diagnostics market.
Johnson & Johnson
JNJ
Mkt Cap579.83B

About

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Show more...
CEO
Mr. Christopher A. Simon
Employees
3657
Country
United States
ISIN
US4050241003

Listings

0 Comments

Share your thoughts

FAQ

What is Haemonetics stock price today?
The current price of HAE is $76.91 USD — it has decreased by -1.65% in the past 24 hours. Watch Haemonetics stock price performance more closely on the chart.
What is Haemonetics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Haemonetics stocks are traded under the ticker HAE.
Is Haemonetics stock price growing?
HAE stock has fallen by -2.29% compared to the previous week, the month change is a +36.63% rise, over the last year Haemonetics has showed a +9.93% increase.
What is Haemonetics market cap?
Today Haemonetics has the market capitalization of 3.57B
When is the next Haemonetics earnings date?
Haemonetics is going to release the next earnings report on August 11, 2026.
What were Haemonetics earnings last quarter?
HAE earnings for the last quarter are 1.29 USD per share, whereas the estimation was 1.27 USD resulting in a +1.36% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Haemonetics revenue for the last year?
Haemonetics revenue for the last year amounts to 2.72B USD.
What is Haemonetics net income for the last year?
HAE net income for the last year is 335.36M USD.
How many employees does Haemonetics have?
As of June 16, 2026, the company has 3,657 employees.
In which sector is Haemonetics located?
Haemonetics operates in the Health & Wellness sector.
When did Haemonetics complete a stock split?
The last stock split for Haemonetics was on December 03, 2012 with a ratio of 2:1.
Where is Haemonetics headquartered?
Haemonetics is headquartered in Boston, United States.